146 related articles for article (PubMed ID: 21524385)
1. Prolactin in breast and prostate cancer: molecular and genetic perspectives.
Jacobson EM; Hugo ER; Borcherding DC; Ben-Jonathan N
Discov Med; 2011 Apr; 11(59):315-24. PubMed ID: 21524385
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.
Lee SA; Haiman CA; Burtt NP; Pooler LC; Cheng I; Kolonel LN; Pike MC; Altshuler D; Hirschhorn JN; Henderson BE; Stram DO
BMC Med Genet; 2007 Dec; 8():72. PubMed ID: 18053149
[TBL] [Abstract][Full Text] [Related]
3. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.
Jacobson EM; Hugo ER; Tuttle TR; Papoian R; Ben-Jonathan N
Trends Endocrinol Metab; 2010 Nov; 21(11):691-8. PubMed ID: 20846877
[TBL] [Abstract][Full Text] [Related]
4. [Prolactin and serotonin].
Lychkovq AE; Puzikov AM
Vestn Ross Akad Med Nauk; 2014; (1-2):38-45. PubMed ID: 25055559
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
6. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
7. Association of prolactin and its receptor gene regions with familial breast cancer.
Vaclavicek A; Hemminki K; Bartram CR; Wagner K; Wappenschmidt B; Meindl A; Schmutzler RK; Klaes R; Untch M; Burwinkel B; Försti A
J Clin Endocrinol Metab; 2006 Apr; 91(4):1513-9. PubMed ID: 16434456
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland.
Nyante SJ; Faupel-Badger JM; Sherman ME; Pfeiffer RM; Gaudet MM; Falk RT; Andaya AA; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Chanock S; Garcia-Closas M; Figueroa JD
Breast Cancer Res; 2011 Apr; 13(2):R42. PubMed ID: 21470416
[TBL] [Abstract][Full Text] [Related]
9. The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications.
Goffin V; Touraine P
Expert Opin Ther Targets; 2015; 19(9):1229-44. PubMed ID: 26063597
[TBL] [Abstract][Full Text] [Related]
10. Prolactin and the prolactin receptor: new targets of an old hormone.
Harris J; Stanford PM; Oakes SR; Ormandy CJ
Ann Med; 2004; 36(6):414-25. PubMed ID: 15513293
[TBL] [Abstract][Full Text] [Related]
11. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
12. Prolactin (PRL) and prolactin receptor (PRLR) genes and their role in poultry production traits.
Wilkanowska A; Mazurowski A; Mroczkowski S; Kokoszyński D
Folia Biol (Krakow); 2014; 62(1):1-8. PubMed ID: 24745142
[TBL] [Abstract][Full Text] [Related]
13. Association of gene polymorphisms in prolactin and its receptor with breast cancer risk in Taiwanese women.
Mong FY; Kuo YL; Liu CW; Liu WS; Chang LC
Mol Biol Rep; 2011 Oct; 38(7):4629-36. PubMed ID: 21125332
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Sakamoto K; Triplett AA; Schuler LA; Wagner KU
Oncogene; 2010 Sep; 29(39):5359-69. PubMed ID: 20639901
[TBL] [Abstract][Full Text] [Related]
15. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
16. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
17. Regulation of prolactin receptor levels and activity in breast cancer.
Swaminathan G; Varghese B; Fuchs SY
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):81-91. PubMed ID: 18204982
[TBL] [Abstract][Full Text] [Related]
18. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
Bogorad RL; Courtillot C; Mestayer C; Bernichtein S; Harutyunyan L; Jomain JB; Bachelot A; Kuttenn F; Kelly PA; Goffin V; Touraine P;
Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14533-8. PubMed ID: 18779591
[TBL] [Abstract][Full Text] [Related]
19. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.
Clevenger CV; Zheng J; Jablonski EM; Galbaugh TL; Fang F
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):147-56. PubMed ID: 18246318
[TBL] [Abstract][Full Text] [Related]
20. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.
Rouet V; Bogorad RL; Kayser C; Kessal K; Genestie C; Bardier A; Grattan DR; Kelder B; Kopchick JJ; Kelly PA; Goffin V
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15199-204. PubMed ID: 20699217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
